Key result
This review summarizes the pathogenesis of cardiac allograft vasculopathy and current management strategies, with a specific focus on the use of mammalian target of rapamycin inhibitors.
Why the study?
Pathogenic mechanisms of CAV remain poorly defined and its overall management remains challenging due to a paucity of treatments.
Answers are grounded in this paper and cite their sources.
This review summarizes the pathogenesis and management of cardiac allograft vasculopathy, highlighting the role of mTOR inhibitors.
Cardiac allograft vasculopathy (CAV) is a unique accelerated form of coronary vascular disease affecting heart transplant recipients. This complication is a significant contributor to medium- to long-term post-transplant morbidity and mortality. There is a high prevalence of CAV with approximately one in three patients developing CAV by 5 years post-transplant. Morphologically, CAV is characterized by concentric coronary intimal hyperplasia in both the epicardial arteries and intramural microvasculature. Although several immune and non-immune factors have been identified, their precise pathogenic mechanisms, interactions, and relative importance in the development of CAV are not well defined. The advent of improved imaging surveillance modalities has resulted in earlier detection during the disease process. However, overall management of CAV remains challenging due to paucity of treatment. This review aims to discuss key concepts on the pathogenesis of CAV and current management strategies, focusing on the use of mammalian target of rapamycin inhibitors.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) conducted a review in Cardiac allograft vasculopathy. Mammalian target of rapamycin inhibitors was evaluated. This review summarizes the pathogenesis of cardiac allograft vasculopathy and current management strategies, with a specific focus on the use of mammalian target of rapamycin inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: